SUPNNasdaqPharmaceutical PreparationsFiscal year ends December 31

SUPERNUS PHARMACEUTICALS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026

$39.84+1.96 (+5.17%)

Close on Oct 19, 2026

Market cap: $2.31B
P/E (TTM): –
Dividend yield: –

SUPERNUS PHARMACEUTICALS, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31
Revenue	719	662	608	667	580	520	393	409	302	215	147	93	12	1.48	0.80	0.11
Cost of Revenue	75	78	84	87	75	52	17	15	15	12	8.42	5.76	1.10	–	–	–
Gross Profit	644	584	524	580	505	468	376	394	287	203	139	87	11	–	–	–
Research & Development	106	109	92	75	90	76	69	89	50	43	29	20	17	24	31	35
Selling, General & Admin	486	322	336	377	305	201	153	155	138	106	89	73	56	20	7.93	5.08
Advertising Expenses	96	89	100	132	86	55	41	43	–	–	–	15	15	5.80	–	–
Total Costs & Expenses	781	580	613	621	494	347	244	264	203	161	127	98	74	44	39	40
Operating Income	-62	82	-5.27	46	86	174	149	144	100	54	21	-5.28	-62	-42	-38	-40
Interest Expense	0	0	2.42	7.07	2.20	19	18	14	0.13	0.54	1.23	4.96	7.85	3.58	1.87	–
Interest & Investment Income	–	–	–	–	–	19	22	14	2.86	1.47	0.68	0.35	0.30	0.12	0.03	0.11
Other Non-Operating Income	13	16	8.04	15	-13	-5.05	-1.08	-4.27	1.08	-3.85	-6.23	-5.02	-30	-4.12	-1.72	0.65
Asset Impairment Charges	0	0	0	0	–	–	–	–	–	0	0	0	0	0	–	–
Gain (Loss) on Investments	–	–	–	–	0.35	4.35	0.30	0	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.03	0.05
Pretax Income	-49	98	2.77	61	73	169	147	140	101	50	15	-10	-92	-46	-39	-39
Income Tax Expense	-10	24	1.45	0.03	20	42	34	29	43	-41	0.67	0.63	0	0	-16	-0.40
Income from Continuing Operations	–	–	–	–	–	–	–	–	–	–	–	–	-92	-46	-23	-39
Income from Discontinued Operations	–	–	–	–	–	–	–	–	–	–	–	–	–	–	77	0.61
Net Income incl. Noncontrolling Interests	–	–	–	–	–	–	–	–	57	91	14	–	–	–	–	–
Net Income	-39	74	1.32	61	53	127	113	111	57	91	14	-11	-92	-46	54	-38
Net Income to Common	-39	74	1.32	64	53	127	113	111	57	91	14	-11	-92	-47	50	-42
EPS (Basic)(per share)	-0.68	1.34	0.02	1.13	1.01	2.41	2.16	2.13	1.13	1.84	0.29	-0.26	-2.90	-2.72	31.39	-26.38
EPS (Diluted)(per share)	-0.68	1.32	0.02	1.04	0.98	2.36	2.10	2.05	1.08	1.76	0.28	-0.26	-2.90	-2.72	31.39	-26.38
Shares Outstanding (Basic, Weighted)(shares)	56	55	55	54	53	53	52	52	51	49	47	42	32	17	1.61	1.59
Shares Outstanding (Diluted, Weighted)(shares)	56	56	56	62	54	54	54	54	53	52	51	42	32	17	1.61	1.59
EBITDA	29	162	80	132	119	192	155	152	108	57	22	-4.35	-61	-41	-37	-39

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 88.1%
Operating margin: -15.7%
Net margin: -13.2%
Return on equity, FY2025: -3.7%

Financial strength

Current ratio: 2.08
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 51.8%

Valuation

P/E ratio: –
Price to sales: 2.79
Price to book: 2.24
Dividend yield: –